Breaking News

TNK Therapeutics to Acquire Virttu Biologics

Gains oncolytic virus therapies to treat cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

TNK Therapeutics, Inc., a subsidiary of Sorrento Therapeutics, Inc., has entered an agreement to acquire Virttu Biologics Ltd.,a privately-held biopharma company focused on developing oncolytic virus therapies to treat cancer. Virttu’s lead product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and elicits an anti-tumor immune response. The oncolytic virus technologies have the potential for broad therapeutic applicat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters